compound 13 [PMID: 23412139]   Click here for help

GtoPdb Ligand ID: 8399

Compound class: Synthetic organic
Comment: This compound is an investigational small molecule inhibitor of beta-site APP-cleaving enzyme 1 (BACE1, β-secretase) [2] (n.b. this is cpd 13 in the reference, not cpd 16 declared as the lead in this article).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 99.82
Molecular weight 338.12
XLogP 1.84
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC#Cc1cncc(c1)c1csc(c1)C1(C)CC(=O)N(C(=N1)N)C
Isomeric SMILES CC#Cc1cncc(c1)c1csc(c1)[C@]1(C)CC(=O)N(C(=N1)N)C
InChI InChI=1S/C18H18N4OS/c1-4-5-12-6-13(10-20-9-12)14-7-15(24-11-14)18(2)8-16(23)22(3)17(19)21-18/h6-7,9-11H,8H2,1-3H3,(H2,19,21)/t18-/m0/s1
InChI Key IKFZEHQGULJMKI-SFHVURJKSA-N
No information available.
Summary of Clinical Use Click here for help
Phase 3 clinical trials are currently underway to evaluate the effectiveness of MK-8931 as a treatment for patients with mild to moderate Alzheimer's disease (AD). (June 2015)